首页> 外文期刊>Applied Microbiology and Biotechnology >Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine
【24h】

Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine

机译:大肠杆菌表达的犬细小病毒衣壳蛋白病毒样颗粒的自组装及其作为病毒样颗粒疫苗的应用

获取原文
获取原文并翻译 | 示例
       

摘要

Canine parvovirus disease is an acute infectious disease caused by canine parvovirus (CPV). Current commercial vaccines are mainly attenuated and inactivated; as such, problems concerning safety may occur. To resolve this problem, researchers developed virus-like particles (VLPs) as biological nanoparticles resembling natural virions and showing high bio-safety. This property allows the use of VLPs for vaccine development and mechanism studies of viral infections. Tissue-specific drug delivery also employs VLPs as biological nanomaterials. Therefore, VLPs derived from CPV have a great potential in medicine and diagnostics. In this study, small ubiquitin-like modifier (SUMO) fusion motif was utilized to express a whole, naturalVP2 protein of CPVin Escherichia coli. After the cleavage of the fusion motif, the CPV VP2 protein has self-assembled into VLPs. The VLPs had a size and shape that resembled the authentic virus capsid. However, the self-assembly efficiency of VLPs can be affected by different pH levels and ionic strengths. The mice vaccinated subcutaneously with CPV VLPs and CPV-specific immune responses were comparedwith those immunizedwith the natural virus. This result showed that VLPs can effectively induce anti-CPV specific antibody and lymphocyte proliferation as a whole virus. This result further suggested that the antigen epitope of CPV was correctly present on VLPs, thereby showing the potential application of a VLP-based CPV vaccine.
机译:犬细小病毒病是由犬细小病毒(CPV)引起的急性传染病。当前的商业疫苗主要是减毒和灭活的。这样,可能会出现与安全有关的问题。为了解决这个问题,研究人员开发了病毒样颗粒(VLP)作为类似于天然病毒粒子的生物纳米颗粒,并显示出很高的生物安全性。该特性允许将VLP用于疫苗开发和病毒感染的机理研究。组织特异性药物递送也采用VLP作为生物纳米材料。因此,源自CPV的VLP在医学和诊断学上具有巨大的潜力。在这项研究中,小的泛素样修饰子(SUMO)融合基序用于表达CPVin大肠杆菌的完整,天然VP2蛋白。切割融合基序后,CPV VP2蛋白已自组装成VLP。 VLP的大小和形状类似于真实的病毒衣壳。但是,VLP的自组装效率会受到不同的pH值和离子强度的影响。将用CPV VLP皮下接种的小鼠和CPV特异性免疫反应与用天然病毒免疫的小鼠进行比较。该结果表明VLP可以作为整体病毒有效诱导抗CPV特异性抗体和淋巴细胞增殖。该结果进一步表明,CPV的抗原表位正确存在于VLP上,从而显示出基于VLP的CPV疫苗的潜在应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号